Candesartan vs Ipilimumab

Candesartan vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Candesartan and Ipilimumab.

Mechanism of Action

Candesartan: Prodrug hydrolyzed to active form; selective angiotensin II type 1 receptor blocker.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Candesartan — 9 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Candesartan — C33H34N6O6.

Molecular Weight: Candesartan — 610.6640 g/mol.

Type: Candesartan — Small molecule; Ipilimumab — Antibody.